Frontiers in Immunology (May 2024)

Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report

  • Wen Dong,
  • Anli Dai,
  • Zhijun Wu,
  • Jiangtao Wang,
  • Tao Wu,
  • Yangfeng Du,
  • Wei Tian,
  • Jiang Zheng,
  • Yan Zhang,
  • Hongming Wang,
  • Juan Cai,
  • Susu Dong,
  • Yan Zhou,
  • Siyan Li,
  • Zemin Xiao

DOI
https://doi.org/10.3389/fimmu.2024.1371379
Journal volume & issue
Vol. 15

Abstract

Read online

SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) is a devastating subtype of thoracic tumor with SMARCA4 inactivation and is characterized by rapid progression, poor prognosis, and high risk of postoperative recurrence. However, effective treatments for SMARCA4-dUT are lacking. Herein, we describe a patient with SMARCA4-dUT who exhibited an impressive response to the anti-programmed cell death protein-1 (PD-1) antibody (tislelizumab) in combination with conventional chemotherapy (etoposide and cisplatin). To the best of our knowledge, this is the first case of SMARCA4-dUT treated with chemotherapy, comprising etoposide and cisplatin, combined with anti-PD-1 inhibitors. Immunotherapy combined with etoposide and cisplatin may be a promising strategy to treat SMARCA4-dUT.

Keywords